NCT02099604View on ClinicalTrials.gov

Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C

PHASE3WithdrawnINTERVENTIONAL

0

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Chronic Hepatitis C

Interventions

DRUG

Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin

Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks

Trial Locations (1)

Unknown

NHTMRI, Cairo

Sponsors

Collaborators (1)

Institut Pasteur

All Listed Sponsors

collaborator

Institut Pasteur

INDUSTRY

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT02099604 - Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C | Biotech Hunter | Biotech Hunter